Compare Novo Nordisk A/S (NVO) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Oatly Group AB - ADR — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Oatly Group AB - ADR trades at $9.21 (market cap $308.50M). The key difference: Novo Nordisk A/S is far larger — about 714.8× Oatly Group AB - ADR's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| NVO | OTLY | |
|---|---|---|
Market Cap | $220.53B | $308.50M |
Sector | Health | Consumer Staples |
52-Week High | $71.70 | $18.54 |
52-Week Low | $35.29 | $8.03 |
Enterprise Value | $239.49B | $806.12M |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Oatly (OTLY) trades at $9.05, down 9.86% in the last session, with a neutral technical signal. The company shows modest revenue growth to $862M in 2025 but continues to report significant losses with a -17.06% net margin. Cash flow remains negative at -$35M, though improving from previous years. Recent news highlights new product launches and upcoming Q2 2026 earnings on July 22.
The outlook remains challenging with persistent losses and high debt levels creating financial strain. Analyst sentiment is mixed with 44% buy ratings but 50% hold, reflecting uncertainty about profitability timeline. Key risks include cash burn sustainability and competitive pressure in the plant-based beverage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
